Generate:Biomedicines Expands C-suite with Chief Corporate Affairs Officer and Chief Technical Operations Officer

Somerville, Mass. – April 30, 2024 – Generate:Biomedicines today announces two key appointments, welcoming Kimberly (Kym) White as the new Chief Corporate Affairs Officer and announcing the promotion of Lisa Wyman to Chief Technical Operations Officer. These appointments not only enhance the company’s leadership team but also reflect its commitment to gender diversity, with over half of the leadership team represented by women. White’s arrival and Wyman’s promotion are instrumental as the company pushes the boundaries of biotechnology, aiming to transform the landscape of drug discovery and development.

Kym White joins the company with a wealth of experience in the biotech and pharmaceutical industries, having held significant roles where she shaped corporate affairs, public policy, and stakeholder engagement strategies. Her deep understanding of the critical role AI can play in advancing human health positions her perfectly to elevate the company’s presence in the biotech industry. As Chief Corporate Affairs Officer, her expertise in healthcare communications will be pivotal in articulating the company’s mission and in driving forward initiatives that showcase the innovative work being done in the field of generative biology.

Lisa Wyman, previously the Senior Vice President of Technical Operations, has been promoted to Chief Technical Operations Officer, with an expanded role that now includes leading the company’s Digital organization. This strategic enhancement of her duties showcases the company’s dedication to integrating its operational excellence with digital capabilities, reinforcing the symbiotic relationship between its pioneering work in generative biology and the latest in digital technologies. Wyman’s distinguished track record in optimizing technical operations, coupled with her visionary leadership in embracing digital transformation, positions her at the forefront of our mission to revolutionize medicine development.

Kym brings a profound understanding of AI’s transformative power in biotech, paired with her expertise in corporate affairs, positioning us to amplify our influence and drive meaningful progress in the industry,” said Mike Nally, CEO of Generate:Biomedicines and CEO-Partner, Flagship Pioneering. Kym’s appointment, alongside Lisa’s expanded position, underscores our commitment to leadership diversity, innovation, and operational excellence. Together, they will propel us toward our mission to program biology to transform how medicines are created, developed, and accessed.”

About Generate:Biomedicines
Generate:Biomedicines is the first drug generation company pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform – which is a continuous loop to generate, build, measure, and learn – can drastically increase the speed at which targets and therapeutics are identified and validated. This will improve the specificity of target engagement by generated proteins and reduce the time and cost of identifying and developing clinical candidates. Generate:Biomedicines is a clinical stage company that was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020. Learn more about Generate:Biomedicines by visiting www​.gen​er​ate​bio​med​i​cines​.com or by following the company on Twitter and LinkedIn.

Generate Media Contact
Megan McLaughlin